HERON THERAPEUTICS INC
HRTXNASDAQ🏆 #3132 by market capUS Equity
$1,003.08▼ $51.26 (−5.11%)
Simulated price1h—
24h▼ 5.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$80M
Small Cap
📈Revenue Growth (YoY)
+1.5%
Slowing
📊Gross Margin
71.1%
High
💵FCF Margin
0.9%
Thin
⚖️P/S Ratio
0.5x
Cheap
Otter Score
46
Weak
No chart data available for HRTX.
Trading Snapshot
- Day Range
- $999.46 – $1,008.54
- 52-Week Range
- $0.38 – $2.30
- Volume
- $3.20B
- Avg Volume
- $3.59B
- Shares Outstanding
- 189.3M
- Next Earnings
- Sep 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $150M
- Last Q Revenue
- $36M
- P/E Ratio
- —
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-0.18
- Dividend Yield
- —
Why Investors Own HRTX
- ✓High-growth profile — revenue up +47.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$150M▲ +43.1% YoY
Gross Margin (TTM)
28.3%▲ +0.1% YoY
Operating Income (TTM)
$20M▲ +43.1% YoY
Free Cash Flow (TTM)
$45M▲ +43.1% YoY
About HERON THERAPEUTICS INC
A company profile for HERON THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$989.45
▼ −1.4% Downside
High Target$1,083.97
Low Target$809.16
Based on 14 analysts
Latest News & Updates
🚀
Barron’s·2h ago
HERON THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift HRTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
HERON THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.